CTLA4 and neoplasm: More recently, a Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)-criteria blinded analysis of p-ERK established that this biomarker predicted OS from a trial in which recurrent GBM patients underwent administration of cavitary and systemic anti-CTLA-4 and anti-PD1 treatments [127].